Lipid management and control of other coronary risk factors in the postmenopausal woman

Journal of Women's Health and Gender-Based Medicine

Volumn 9, Issue 3, 2000, Pages 235-243

  Wenger, Nanette Kass ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; MEDROXYPROGESTERONE; PRAVASTATIN; SIMVASTATIN;

BREAST CARCINOGENESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIET THERAPY; EXERCISE; FEMALE; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; OBESITY; POSTMENOPAUSE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; REVIEW;

CORONARY DISEASE; FEMALE; HUMANS; HYPERLIPIDEMIAS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 0342313754     PISSN: 15246094     EISSN: None     Source Type: Journal    
DOI: 10.1089/152460900318443     Document Type: Review

References (31)

1. American Heart Association. 1999 heart and stroke statistical update. Dallas, TX: Author, 1998.
2. Wenger N. Women, myocardial infarction, and coronary revascularisation: Concordant and discordant clinical trial and registry data. Cardiol Rev 1999;7:117.
3. Wenger NK. Coronary heart disease: An older woman's major health risk. BMJ 1997;315:1085.
4. Oparil S. Pathophysiology of sudden coronary death in women. Implications for prevention. Circulation 1998;97:2103.
5. Marrugat J, Sala J, Masia R, et al. Mortality differences between men and women following first myocardial infarction. RESCATE Investigators. Recursos Empleados en el Sindrome Coronario Agudo y Tiempo de Espera. JAMA 1998;280:1405.
6. Chandra NC, Ziegelstein RC, Rogers WJ, et al. Observations of the treatment of women in the United States with myocardial infarction: A report from the National Registry of Myocardial Infarction-I. Arch Intern Med 1998;158:981.
7. Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med 1999;340:618.
8. Edwards FH, Carey JS, Grover FL, Bero JW, Hartz RS. Impact of gender on coronary bypass operative mortality. Ann Thorac Surg 1998;66:125.
9. Jacobs AK, Kelsey SF, Brooks MM, et al. Better outcome for women compared with men undergoing coronary revascularization: A report from the Bypass Angioplasty Revascularization Investigation (BARI) Circulation 1998;98:1279.
10. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med 1993;329: 247.
11. Kannel WB. Metabolic risk factors for coronary heart disease in women: Perspective from the Framingham Study. Am Heart J 1987;114:413.
12. Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids and lipoproteins in healthy women. Atherosclerosis 1993;98:83.
13. Shelley JM, Green A, Smith AM, et al. Relationship of endogenous sex hormones to lipids and blood pressure in mid-aged women. Ann Epidemiol 1998;8:39.
14. Schrott HG, Bittner V, Vittinghoff E, Herrington DM, Hulley S. Adherence to National Cholesterol Education Program treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). JAMA 1997;277:1281.
15. Gueyffier F, Boutitie F, Boissel JP, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997;126:761.
16. Sowers JR. Diabetes mellitus and cardiovascular disease in women. Arch Intern Med 1998;158:617.
17. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67: 968.
18. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279:1615.
19. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349.
20. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
21. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The Cholesterol and Recurrent Events (CARE) trial. J Am Coll Cardiol 1998;32:140.
22. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lesperance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation 1995; 92:2404.
23. National Cholesterol Education Program Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015.
24. Grodstein F, Stampfer MJ, Colditz GA, et al. Post-menopausal hormone therapy and mortality. N Engl J Med 1997;336:1769.
25. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605.
26. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199.
27. Weintraub MS, Grosskopf I, Charach G, et al. Fluctuations of lipid and lipoprotein levels in hyperlipidemic postmenopausal women receiving hormone replacement therapy. Arch Intern Med 1998;158:1803.
28. Bass KM, Newschaffer CJ, Klag MJ, Bush TL. Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 1993;153:2209.
29. JNC-VI. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413.
30. Rosenberg L, Palmer JR, Shapiro S. Decline in the risk of myocardial infarction among women who stop smoking. N Engl J Med 1990;322:213.
31. Lemaitre RN, Heckbert SR, Psaty BM, Siscovick DS. Leisure-time physical activity and the risk of nonfatal myocardial infarction in postmenopausal women. Arch Intern Med 1995;155:2302.